Search

Search Constraints

You searched for: Author/Creator Mine, Hayato

Search Results

1. A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib. Issue 15 (23rd June 2021)

2. Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004). (March 2021)

4. Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: A case report. Issue 19 (5th September 2022)